O	0	5	Phase
O	6	9	III
O	10	15	study
O	16	18	of
B-intervention	19	28	letrozole
O	29	35	versus
B-control	36	45	tamoxifen
O	46	48	as
O	49	54	first
O	54	55	-
O	55	59	line
O	60	67	therapy
O	68	70	of
O	71	79	advanced
O	80	86	breast
O	87	93	cancer
O	94	96	in
O	97	111	postmenopausal
O	112	117	women
O	117	118	:
O	119	127	analysis
O	128	130	of
O	131	139	survival
O	140	143	and
O	144	150	update
O	151	153	of
O	154	162	efficacy
O	163	167	from
O	168	171	the
O	172	185	International
O	186	195	Letrozole
O	196	202	Breast
O	203	209	Cancer
O	210	215	Group
O	215	216	.

O	217	219	To
O	220	227	analyze
O	228	235	overall
O	236	244	survival
O	245	246	(
O	246	248	OS
O	248	249	)
O	250	253	and
O	254	260	update
O	261	269	efficacy
O	270	274	data
O	275	278	for
O	279	288	letrozole
O	289	295	versus
O	296	305	tamoxifen
O	306	308	as
O	309	314	first
O	314	315	-
O	315	319	line
O	320	327	therapy
O	328	330	in
O	331	345	postmenopausal
O	346	351	women
O	352	356	with
O	357	364	locally
O	365	373	advanced
O	374	376	or
O	377	387	metastatic
O	388	394	breast
O	395	401	cancer
O	401	402	.

O	403	407	This
O	408	419	multicenter
O	420	425	phase
O	426	429	III
O	430	435	trial
O	436	444	randomly
O	445	453	assigned
B-total-participants	454	457	916
B-eligibility	458	466	patients
I-eligibility	467	471	with
I-eligibility	472	479	hormone
I-eligibility	480	488	receptor
I-eligibility	488	489	-
I-eligibility	489	497	positive
I-eligibility	498	500	or
I-eligibility	501	508	unknown
I-eligibility	509	515	tumors
O	516	525	letrozole
O	526	527	2
O	527	528	.
O	528	529	5
O	530	532	mg
O	533	534	(
O	534	535	n
O	536	537	=
B-intervention-participants	538	541	458
O	541	542	)
O	543	545	or
O	546	555	tamoxifen
O	556	558	20
O	559	561	mg
O	562	563	(
O	563	564	n
O	565	566	=
B-control-participants	567	570	458
O	570	571	)
O	572	577	daily
O	578	583	until
O	584	591	disease
O	592	603	progression
O	603	604	.

O	605	613	Optional
O	614	619	cross
O	619	620	-
O	620	624	over
O	625	628	was
O	629	638	permitted
O	639	641	at
O	642	645	the
O	646	654	treating
O	655	664	physician
O	664	665	'
O	665	666	s
O	667	677	discretion
O	677	678	.

O	679	683	This
O	684	690	report
O	691	698	updates
O	699	707	efficacy
O	708	710	at
O	711	712	a
O	713	719	median
O	720	726	follow
O	726	727	-
O	727	729	up
O	730	732	of
O	733	735	32
O	736	742	months
O	742	743	.

O	744	747	The
O	748	759	superiority
O	760	762	of
O	763	772	letrozole
O	773	775	to
O	776	785	tamoxifen
O	786	789	was
O	790	799	confirmed
O	800	803	for
B-outcome	804	808	time
I-outcome	809	811	to
I-outcome	812	823	progression
O	824	825	(
O	825	831	median
O	831	832	,
B-iv-cont-median	833	834	9
I-iv-cont-median	834	835	.
I-iv-cont-median	835	836	4
O	837	838	v
B-cv-cont-median	839	840	6
I-cv-cont-median	840	841	.
I-cv-cont-median	841	842	0
I-cv-cont-median	843	849	months
O	849	850	,
O	851	863	respectively
O	863	864	;
O	865	866	P
O	867	868	<
O	868	869	.
O	869	873	0001
O	873	874	)
O	874	875	,
B-outcome	876	880	time
I-outcome	881	883	to
I-outcome	884	893	treatment
I-outcome	894	901	failure
O	902	903	(
O	903	909	median
O	909	910	,
B-iv-cont-median	911	912	9
O	913	914	v
B-cv-cont-median	915	916	5
I-cv-cont-median	916	917	.
I-cv-cont-median	917	918	7
I-cv-cont-median	919	925	months
O	925	926	,
O	927	939	respectively
O	939	940	;
O	941	942	P
O	943	944	<
O	944	945	.
O	945	949	0001
O	949	950	)
O	950	951	,
B-outcome	952	959	overall
I-outcome	960	969	objective
I-outcome	970	978	response
I-outcome	979	983	rate
O	984	985	(
B-iv-bin-percent	985	987	32
I-iv-bin-percent	987	988	%
O	989	990	v
B-cv-bin-percent	991	993	21
I-cv-bin-percent	993	994	%
O	994	995	,
O	996	1008	respectively
O	1008	1009	;
O	1010	1011	P
O	1012	1013	=
O	1013	1014	.
O	1014	1018	0002
O	1018	1019	)
O	1019	1020	,
O	1021	1024	and
B-outcome	1025	1032	overall
I-outcome	1033	1041	clinical
I-outcome	1042	1049	benefit
O	1049	1050	.

B-outcome	1051	1057	Median
I-outcome	1058	1060	OS
O	1061	1064	was
O	1065	1073	slightly
O	1074	1083	prolonged
O	1084	1087	for
O	1088	1091	the
O	1092	1102	randomized
O	1103	1112	letrozole
O	1113	1116	arm
O	1117	1118	(
B-iv-cont-median	1118	1120	34
O	1121	1122	v
B-cv-cont-median	1123	1125	30
I-cv-cont-median	1126	1132	months
O	1132	1133	,
O	1134	1146	respectively
O	1146	1147	)
O	1147	1148	.

O	1149	1157	Although
O	1158	1162	this
O	1163	1173	difference
O	1174	1176	in
O	1177	1179	OS
O	1180	1182	is
O	1183	1186	not
O	1187	1198	significant
O	1198	1199	,
O	1200	1208	survival
O	1209	1212	was
O	1213	1221	improved
O	1222	1224	in
O	1225	1228	the
O	1229	1239	randomized
O	1240	1249	letrozole
O	1250	1253	arm
O	1254	1258	over
O	1259	1262	the
O	1263	1268	first
O	1269	1270	2
O	1271	1276	years
O	1277	1279	of
O	1280	1283	the
O	1284	1289	study
O	1289	1290	.

O	1291	1304	Approximately
O	1305	1308	one
O	1309	1313	half
O	1314	1316	of
O	1317	1320	the
O	1321	1329	patients
O	1330	1332	in
O	1333	1337	each
O	1338	1341	arm
O	1342	1349	crossed
O	1350	1354	over
O	1354	1355	.

O	1356	1361	Total
O	1362	1370	duration
O	1371	1373	of
O	1374	1383	endocrine
O	1384	1391	therapy
O	1392	1393	(
B-outcome	1393	1394	"
I-outcome	1394	1398	time
I-outcome	1399	1401	to
I-outcome	1402	1414	chemotherapy
I-outcome	1414	1415	"
O	1415	1416	)
O	1417	1420	was
O	1421	1434	significantly
O	1435	1441	longer
O	1442	1443	(
O	1443	1444	P
O	1445	1446	=
O	1446	1447	.
O	1447	1450	005
O	1450	1451	)
O	1452	1455	for
O	1456	1464	patients
O	1465	1474	initially
O	1475	1477	on
O	1478	1487	letrozole
O	1488	1489	(
O	1489	1495	median
O	1495	1496	,
B-iv-cont-median	1497	1499	16
I-iv-cont-median	1500	1506	months
O	1506	1507	)
O	1508	1512	than
O	1513	1516	for
O	1517	1525	patients
O	1526	1535	initially
O	1536	1538	on
O	1539	1548	tamoxifen
O	1549	1550	(
O	1550	1556	median
O	1556	1557	,
B-cv-cont-median	1558	1559	9
I-cv-cont-median	1560	1566	months
O	1566	1567	)
O	1567	1568	.

B-outcome	1569	1573	Time
I-outcome	1574	1576	to
I-outcome	1577	1586	worsening
O	1587	1589	of
O	1590	1599	Karnofsky
O	1600	1611	performance
O	1612	1617	score
O	1618	1621	was
O	1622	1635	significantly
O	1636	1643	delayed
O	1644	1648	with
O	1649	1658	letrozole
O	1659	1667	compared
O	1668	1672	with
O	1673	1682	tamoxifen
O	1683	1684	(
O	1684	1685	P
O	1686	1687	=
O	1687	1688	.
O	1688	1691	001
O	1691	1692	)
O	1692	1693	.

O	1694	1698	This
O	1699	1704	study
O	1705	1714	documents
O	1715	1718	the
O	1719	1730	superiority
O	1731	1733	of
O	1734	1743	letrozole
O	1744	1748	over
O	1749	1758	tamoxifen
O	1759	1761	in
O	1762	1767	first
O	1767	1768	-
O	1768	1772	line
O	1773	1782	endocrine
O	1783	1790	therapy
O	1791	1793	in
O	1794	1808	postmenopausal
O	1809	1814	women
O	1815	1819	with
O	1820	1828	advanced
O	1829	1835	breast
O	1836	1842	cancer
O	1842	1843	.
